Skip to main content Help with accessibility Skip to main navigation

All Guidance

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - November - 2018
BNF chapter: Central nervous system

Methylphenidate, Lisdexamfetamine, Dexamfetamine, Atomoxetine - For Attention Deficit Hyperactivity Disorder in adults aged over 17 years and in children and adolescents aged 6 to 17 years

Guanfacine - For Attention Deficit Hyperactivity Disorder in children and adolescents aged 6 to 17 years 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 31 - August - 2018
BNF chapter: Endocrine system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Pending
Date Posted: 14 - January - 2021
BNF chapter: Cardiovascular system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - November - 2014
BNF chapter: Central nervous system

Amisulpride, Aripiprazole, Olanzapine, Quetiapine, Oral Risperidone
This shared prescribing guideline for the second-generation antipsychotic medications listed above has been developed with due consideration to the appropriate NICE Clinical Guidelines (CG) e.g. Bipolar Disorder (CG185), Psychosis and Schizophrenia in Children and Young People (CG155), Psychosis and Schizophrenia in Adults (CG178), Schizophrenia- Aripiprazole (TA213), Bipolar Disorder- Adolescents (TA292).

Please note: Morecambe Bay CCG has now adopted this Shared-care guideline for all areas, including South Cumbria. 

 

Adopted
Pending
Adopted
Adopted
Pending
Adopted
Adopted
Adopted
Date Posted: 01 - January - 2017
BNF chapter: Central nervous system

Refer to Local Commissioning Policy Before Use

Treatment of Parkinson’s Disease

 

 

Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2018
BNF chapter: Endocrine system
Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2018
BNF chapter: Endocrine system
Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Pending
Date Posted: 15 - July - 2020
BNF chapter: Central nervous system
This guideline provides recommendations on the medical management of adults with chronic non-cancer pain.

 

Adopted
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Pending
Date Posted: 12 - September - 2022
BNF chapter: Respiratory system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 15 - November - 2022
BNF chapter: Respiratory system

This asthma summary guideline has been created in collaboration with the Lancashire and South Cumbria Clinical Asthma Group led by Dr Aashish Vyas, with the aim to provide a consistent approach to asthma treatment for adults within LSCMMG.

BTS/SIGN British Guideline on the Management of Asthma

NICE NG80 - Asthma: diagnosis, monitoring and Chronic Asthma Management

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Pending
Date Posted: 19 - February - 2020
BNF chapter: Respiratory system
Adopted
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Adopted
Date Posted: 24 - October - 2022
BNF chapter: Cardiovascular system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 13 - May - 2022

Radiographic (Ankylosing Spondylitis) and Non-radiographic Axial Spondyloarthritis (ASp) LSCMMG Recommended Biologic Pathway

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted

This guidance does not replace the SPC’s, which should be read in conjunction with this guidance.

***Please note: the clinical content of the DMARD shared care documents has now been updated in accordance with the relevant SPCs and national guidance. However, LSCMMG has approved an interim expiry of six months from June 2022 to allow for the completion of the DMARD shared-care pathway work which is still ongoing. We expect the full update to be published by December 2022. Please contact mlcsu.medicinesmanagement@nhs.net for further information***

 

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - June - 2015
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 12 - September - 2019
BNF chapter: Skin

Medical camouflaging products must only be initiated by a healthcare professional that specialises in skin colour matching and appropriate application techniques.
Please note: these products must only be continued in primary care if the patient’s GP believes issuing such a prescription will continue to significantly reduce the impact of the patient’s medical condition.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - January - 2019
BNF chapter: Central nervous system

This guidance does not apply to the use of Sativex® (delta-9-etrahydrocannabinol and cannabidiol) oromucosal spray as an adjunct treatment for moderate to severe spasticity in multiple sclerosis.

**This Guideline is currently under review. For further information please click here**
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Pending
Date Posted: 19 - July - 2022
BNF chapter: Central nervous system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted

This guidance does not replace the SPC’s, which should be read in conjunction with this guidance

***Please note: the clinical content of the DMARD shared care documents has now been updated in accordance with the relevant SPCs and national guidance. However, LSCMMG has approved an interim expiry of six months from June 2022 to allow for the completion of the DMARD shared-care pathway work which is still ongoing. We expect the full update to be published by December 2022. Please contact mlcsu.medicinesmanagement@nhs.net for further information***

 

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - November - 2016

NHS England has advised CCGs that a prescription for the treatment of infrequent constipation should not routinely be offered in primary care as the condition is appropriate for self-care. The NHS England guidance applies to short term, infrequent constipation caused by changes in lifestyle or diet such as lack of water or movement or changes in diet. GPs should continue to prescribe laxatives to manage acute constipation with more complex aetiology (e.g. iatrogenic) and chronic constipation.

The NHS England guidance does not apply to the management of children and laxatives for children should continue to be prescribed by GPs.